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Abstract
Objective: Securin, the product of PTTG (pituitary tumor transforming 
gene), is overexpressed in several tumors, and plays important roles in 
cancer progression and invasion. In our previous report, securin expres-
sion was observed in transitional cell carcinoma (TCC; the most common 
pathological pattern of bladder cancer) cell lines, including BFTC905, 
T24, and TSGH8301. However, the existence of securin in human bladder 
cancer specimens has not been established.
Materials and Methods: Commercial bladder cancer tissue arrays (BL208 & 
BLC661) were used. Slides of paraffin-fixed human bladder tissues 
included all grades of TCC (18, 22 and 29 tissue samples for grades I, II, 
and III, respectively), 21 superficial and 41 invasive TCC specimens, and 11 
normal urothelial tissue samples. The intensities of securin immunostaining 
were graded as background, mild, and strong (scored as 0, 1, and 2, respec-
tively), and scores from the nucleus and cytosol were analyzed separately.
Results: We have demonstrated, for the first time, the expression of securin 
in bladder tissues. Securin was overexpressed in the cytosol and nucleus 
of all TCC samples compared to normal urothelium, but only cytosolic local-
ization revealed statistical significance. There were no differences in securin 
immunoreactivity among the different grades of TCC. Significant over-
expression of cytosolic but not nuclear securin was found in both superficial 
and invasive TCC samples compared to normal urothelium. No difference 
in immunoreactive staining for nuclear and cytosolic securin between 
superficial and invasive TCC was noted.
Conclusion: Significant enhanced expression of cytosolic securin protein 
was found in human bladder cancer specimens, suggesting that the level 
of tissue securin may be a potential biomarker for the diagnosis of blad-
der cancer. Studies that investigate the relationship between securin 
expression and the outcomes of bladder cancer patients could be con-
ducted in the future. [Tzu Chi Med J 2010;22(4):171–176]
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1. Introduction
Urinary bladder cancer is among the nine most com-
monly diagnosed cancers in the world [1]. Patho-
logically, more than 90% of bladder cancers are 
transitional cell carcinoma (TCC), but small numbers 
of other histological types, such as squamous cell car-
cinoma and adenocarcinoma, have also been reported 
[2,3]. Histological findings revealed by microscope 
examination as well as clinical staging determined 
by imaging are the most common tools to evaluate 
the management and to predict the outcome of blad-
der cancer. The TNM system provides a detailed stag-
ing classification, but the invasive status divided into 
superficial and muscle-invading types is easier to use. 
There are some correlations between tumor grades 
and stages. Most well and moderately differentiated 
tumors are superficial and most poorly differentiated 
tumors are invasive into muscle [4].
Many proteins have been examined for potential 
roles as diagnostic or screening markers for bladder 
cancer detection [5]. However, the use of these mo-
lecular markers is usually not practical for extensive 
clinical application [6]. Survivin, for example, is an ex-
cellent urinary marker for bladder cancer detection 
[7–9]. Furthermore, survivin expression indicates a 
poor outcome and serves as a recurrent marker in 
bladder cancer patients [10–13]. However, our inves-
tigation (unpublished results) revealed some discrep-
ant data between the in vitro cytotoxic effects and 
survivin expression after lestaurtinib treatment in TCC 
cells. Thus, a new marker for outcome monitoring of 
bladder cancer patients is needed.
Pituitary tumor-derived transforming gene (PTTG) 
was originally identified from rat pituitary tumor [14]. 
Subsequent studies demonstrated that human se-
curin is identical to the product of PTTG [15]. Over-
expression of securin has been observed in several 
human neoplasms other than pituitary tumors, e.g., 
carcinoma of the breast [16], esophagus [17], and 
liver [18]. In addition, high level expression of securin 
is associated with the invasiveness and aggressive-
ness of thyroid cancer [19]. Securin is also thought to 
be a proliferation marker and outcome indicator of 
invasive ductal breast cancer [20]. In our previous 
study, securin was easily detected by Western blot 
analysis in three TCC cell lines, i.e., BFTC905, T24, 
and TSGH8301 [21]. Inhibition of securin expression 
by TrkB blockade was followed by cytotoxicity [21]. As 
far as we know, there are no studies investigating the 
expression of securin in human bladder cancer tis-
sues. In this study, we report the expression of securin 
in human bladder cancer specimens. We found sig-
nificantly elevated cytosolic securin expression in all 
TCC samples regardless of grade or stage, or whether 
it is superficial or invasive.
2. Materials and methods
2.1. Surgical specimens from commercial 
tissue arrays
Slides of paraffin-fixed human bladder tissues includ-
ing all grades/stages of TCC, and normal urothelial 
tissues from a total of 102 patients were purchased 
from Biomax, Inc. (BL208 & BLC661; Rockville, MD, 
USA). Sarcoma, squamous cell carcinoma and adeno-
carcinoma, and sections with absence of urothelial 
tissues were excluded from this study. Finally, exam-
ined tissues included 11 normal urothelial samples 
and 69 TCC cases. The case numbers of grades I, II 
and III TCC were 18, 22 and 29, respectively. Some 
neoplastic tissues were graded within a range (e.g., 
II–III), but for subsequent analysis, they were as-
signed to the higher grade (i.e., III). Some TCC tis-
sues without definite staging (TxN0M0 mentioned on 
the list) were also excluded from further analysis. 
Thus, the case numbers of superficial (TisN0M0 and 
T1N0M0) and invasive type (≥ T2NxMx) were 21 and 41, 
respectively.
2.2. Immunohistochemical staining
The protocol and agents used for immunohistochem-
ical staining have been previously described [22]. 
Initial steps included deparaffinization, rehydration, 
antigen retrieval, endogenous peroxidase quenching, 
and background blocking. Sections were incubated 
for 48 hours at 4°C with primary anti-securin mono-
clonal antibodies (1:200, ab3305; Abcam, Cambridge, 
MA, USA). Horseradish peroxidase-conjugated sec-
ondary antibodies were added for 30 minutes [Novo-
Link polymer; Novocastra, Leica Microsystems (UK) 
Ltd., Milton Keynes, Bucks, UK], and substrate 3,3’-
diaminobenzidine (Dako Denmark A/S, Glostrup, 
Denmark) was added for 5 minutes. Strong, weak, 
and no immunoreactive staining of the nucleus or 
cytosol were scored as 2, 1, and 0, respectively [23]. 
The tissues were viewed under a microscope (×400), 
and the scores were confirmed by other staff mem-
bers. A representative scored sample is demonstrated 
in Fig. 1.
2.3. Statistical analysis
The average score for each grade or stage was ex-
pressed as mean ± standard error of the mean. The dif-
ferences in the immunoreactive scores among each 
group were evaluated by nonparametric Mann-Whitney 
t test. In all cases, a significant difference was accepted 
at p < 0.05.
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3. Results
3.1. Securin is overexpressed in the 
nucleus and cytosol of TCC 
specimens
The difference in immunoreactive scores for cytosolic 
securin between normal urothelium and all TCC sam-
ples reached statistical significance (0.45 ± 0.16 vs. 
1.04 ± 0.06 for normal urothelium vs. TCC, respec-
tively; p = 0.006; Fig. 2). Although nuclear securin in 
TCC tissues was also overexpressed compared to 
normal urothelium (0.73 ± 0.30 vs. 1.23 ± 0.08, nor-
mal urothelium vs. TCC, respectively), the difference 
did not reach statistical significance (p = 0.09).
3.2. Securin is overexpressed in the 
nucleus and cytosol of each grade 
of TCC
Securin immunostaining in all grades of TCC (1.11 ± 
0.11, 0.91 ± 0.09, and 1.10 ± 0.10 for grades I, II, and 
III TCC samples, respectively) showed statistically 
higher scores in the cytosol than that of normal urothe-
lium (p = 0.01, 0.04, and 0.009; grades I, II, and III 
TCC vs. normal urothelium; Fig. 3). However, there was 
no difference in nuclear securin expression between 
normal urothelium and each grade of TCC. In addi-
tion, securin expression among each grade of TCC, 
both in the nucleus and cytosol, did not reach statis-
tical significance.
Fig. 1 — Immunohistochemical staining of securin in TCC 
and normal urothelial specimens. Representative immuno-
reactive scoring in tissue samples. The arrow and arrowhead 
indicate the cytosol and nucleus, respectively. (A) Normal 
urothelium, score of 0 for both the nucleus and cytosol. 
(B) Grade 1 and T1N0M0 TCC tissue, score of 1 for both the 
nucleus and cytosol. (C) Grade 3 and T3N0M0 TCC tissue, 
score of 2 for both the nucleus and cytosol.
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Fig. 2 — Securin immunostaining scores for all TCC 
samples. The average cytosolic and nuclear securin scores 
for TCC and normal urothelial tissue samples. *p < 0.05.
174 TZU CHI MED J  December 2010  Vol 22  No 4
3.3. Securin is overexpressed in the 
nucleus and cytosol of superficial and 
invasive TCC
Cytosolic securin was overexpressed in the superficial 
and invasive TCC samples (0.95 ± 0.11 and 1.12 ± 
0.08, respectively) compared to normal urothelium 
(p = 0.04 and 0.004, respectively; Fig. 4). However, 
there was no difference in nuclear securin expression 
between normal urothelium and superficial or inva-
sive TCC samples. In addition, no difference in nuclear 
and cytosolic securin expression between superficial 
and invasive TCC was found.
4. Discussion
Although securin is expressed at a low level or is even 
absent in most normal tissues [14], its mRNA has 
been observed in some normal human cells, e.g., the 
testis, small intestine, and fetal liver [24]. Securin binds 
separase to inactivate the latter’s proteolytic activity 
during metaphase to prevent sister chromatid sepa-
ration [25]. During the metaphase–anaphase transi-
tion, securin is degraded by ubiquitin ligase [26]. In 
addition, DNA double-strand breaks prevent the as-
sociation of securin and Ku-70, the regulatory subu-
nit of the DNA-dependent protein kinase, resulting in 
DNA repair by Ku-70 activation [27]. Thus, it is not 
surprising that securin expression is found in these 
proliferative normal tissues and functions as a regu-
lator of the cell cycle. Urothelium is also one type of 
proliferative epithelial cell. No investigations examin-
ing the securin expression in urinary bladder tissue 
have been reported. In this study, 6 of 11 normal 
cytosolic and 7 of 11 normal nuclear urothelial tissues 
did not show immunostaining for securin. But strong 
nuclear immunostaining for securin was found in 4 
of 11 normal urothelium samples. Therefore, securin 
may also play some role in the cell cycle and DNA re-
pair of normal urothelium. The signaling of securin in 
urothelium proliferation remains to be investigated.
Both subcellular localization of securin in the nu-
cleus and/or cytoplasm in various cell lines and tissue 
types was reported and summarized by Salehi et al 
[28]. Translocation of securin from the cytoplasm to 
the nucleus is mediated by some molecules such as 
PBF (PTTG-binding factor) [29], and mitogen-activated 
protein kinase cascades [30]. Nuclear expression of 
securin functions as the inhibitor of premature sister 
chromatid separation, while cytoplasmic expression 
is thought to be a transcriptional factor [15,31,32]. 
The significance of securin localization remains un-
clear in cancer biology. Thus, we analyzed the sub-
cellular localization of securin expression in human 
bladder cancer tissues.
In the present study, abundant securin expression 
was found in both the cytosol and nucleus of all grades 
and all TCC tissues compared to normal urothelium. 
Although we did not observe a significant difference 
for nuclear securin expression between normal and 
cancerous urothelium, which might be due to the lim-
ited number of samples used, especially of normal 
urothelium, there was a trend toward elevated ex-
pression in bladder cancer specimens. These results 
are similar to those for adenocarcinoma of the breast 
and lung [33,34]. However, predominant nuclear lo-
calization was found in patients with glioma [35], while 
predominant cytoplasmic expression was found in 
patients with pituitary adenoma [36]. Although the 
roles of its expression in the nucleus or cytosol of 
Fig. 3 — Securin scores for all grades of TCC. The average 
cytosolic and nuclear securin scoring differences between 
each grade of TCC (grades I, II, and III) tissues and normal 
urothelium (N). *p < 0.05.
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Fig. 4 — Securin scores for both superficial and invasive 
TCC samples. The average cytosolic and nuclear scoring dif-
ferences for securin expression between superficial (S)/
invasive (I) TCC tissues and normal urothelium (N). *p < 0.05.
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TCC should be further investigated, our data indicate 
that securin undoubtedly plays important roles in the 
tumorigenesis of TCC. Due to the distinct difference 
in its expression between TCC and normal urothelium, 
securin might have the potential to become a new 
biomarker for TCC screening.
Recent evidence has demonstrated the correlation 
between securin and the invasive abilities of some 
cancers. A high recurrence rate has been noted in 
breast cancer patients with overexpression of se-
curin [37]. High securin expression in colorectal and 
esophageal cancer has been demonstrated to corre-
late with lymph node metastasis [38,39]. Follicular 
thyroid carcinoma grown in PTTG–/– mice exhibited a 
significant reduction in vascular invasion and less de-
velopment of lung metastasis when these mice pro-
gressively aged [40]. Knock-down securin by siRNA 
also inhibited the invasion of glioma cells in vitro 
[34]. Thus, securin indeed plays important roles in 
neoplasmic invasiveness. Both cytosolic and nuclear 
securin overexpression in superficial and invasive TCC 
tissue was found in this study, but only cytosolic lo-
calization revealed statistical significance. Therefore, 
the precise role of securin in the invasive ability of 
TCC remains unclear.
Only 69 human TCC tissues and 11 normal urothe-
lial samples were examined in our study. The exis-
tence of a correlation between securin expression and 
the severity of TCC, if present, cannot be completely 
confirmed, and larger numbers of samples should be 
collected and evaluated. In addition, the immunohis-
tochemical staining score is not a perfect method for 
quantification of the target protein. In future investi-
gations, securin detected by Western blot or enzyme-
linked immunosorbent assays in fresh TCC samples 
will be needed to determine the relationship between 
clinical outcome and expression levels of securin.
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